Vivani Medical price to sales ratio VANI

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 6.1×; Aug 2020
10-year median: 14.9×
10-year range: 3.9× to 24.1×
Peer median: 1.4×

Vivani Medical's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Aug 2020, at 6.1×.

On the days it had one over the last ten years, its median was 14.9×, from 3.9× in Apr 2020 to 24.1× in Nov 2019.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2020	6.1×	3.9×	20.3×
2019	19.8×	6.1×	24.1×
2018	8.3×	6.7×	20.9×
2017	19.5×	10.7×	20.5×
2016	18.2×	14.6×	28.6×

Against its peers

Companies in Healthcare nearest Vivani Medical's size, closest first, today.

Company	Price to sales ratio
VANIVivani Medical	n/m
KEQUKewaunee Scientific	0.3×
ICCCImmucell	3.0×
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
APTAlpha Pro Tech	0.9×
PDEXPro DEX	2.6×
PLXProtalix BioTherapeutics	2.5×
ATNMActinium Pharmaceuticals	n/m
NATRNatures Sunshine Products	0.4×
ELMDElectromed	3.0×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Vivani Medical

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.